Publications by authors named "Julia Strangmann"

Background: Esophageal cancer is one of the 10 most common cancers worldwide and its incidence is dramatically increasing. Despite some improvements, the current surveillance protocol with white light endoscopy and random untargeted biopsies collection (Seattle protocol) fails to diagnose dysplastic and cancerous lesions in up to 50% of patients. Therefore, new endoscopic imaging technologies in combination with tumor-specific molecular probes are needed to improve early detection.

View Article and Find Full Text PDF

Barrett's esophagus (BE) is a precursor of the esophageal adenocarcinoma (EAC). BE- development and its progression to cancer is associated with gastroesophageal reflux disease. However, there is currently no molecular risk prediction model that accurately identifies patients at high risk for EAC.

View Article and Find Full Text PDF

Background: Near-infrared (NIR) fluorescence imaging has been emerging as a promising strategy to overcome the high number of early esophageal adenocarcinomas missed by white light endoscopy and random biopsy collection. We performed a preclinical assessment of fluorescence imaging and endoscopy using a novel CXCR4-targeted fluorescent peptide ligand in the L2-IL1B mouse model of Barrett's esophagus.

Methods: Six L2-IL1B mice with advanced stage of disease (12-16 months old) were injected with the CXCR4-targeted, Sulfo-Cy5-labeled peptide (MK007), and ex vivo wide-field imaging of the whole stomach was performed 4 h after injection.

View Article and Find Full Text PDF

Esophageal adenocarcinoma (EAC) is mostly prevalent in industrialized countries and has been associated with obesity, commonly linked with a diet rich in fat and refined sugars containing high fructose concentrations. In meta-organisms, dietary components are digested and metabolized by the host and its gut microbiota. Fructose has been shown to induce proliferation and cell growth in pancreas and colon cancer cell lines and also alter the gut microbiota.

View Article and Find Full Text PDF

Purpose: The incidence of esophageal adenocarcinoma (EAC) has been increasing for decades without significant improvements in treatment. Barrett's esophagus (BE) is best established risk factor for EAC, but current surveillance with random biopsies cannot predict progression to cancer in most BE patients due to the low sensitivity and specificity of high-definition white light endoscopy.

Methods: Here, we evaluated the membrane-bound highly specific Hsp70-specific contrast agent Tumor-Penetrating Peptide (Hsp70-TPP) in guided fluorescence molecular endoscopy biopsy.

View Article and Find Full Text PDF
Article Synopsis
  • Barrett's esophagus (BE) is a condition that often leads to esophageal adenocarcinoma (EAC), primarily caused by chronic gastroesophageal reflux disease (GERD) and influenced by factors like obesity and diet.
  • Current risk prediction methods and endoscopic surveillance for EAC have limited effectiveness, prompting interest in using chemopreventive strategies to reduce cancer risks.
  • In mouse studies, treatments with anti-inflammatory drugs (like Anakinra and NSAIDs) showed promise in slowing tumor growth and altering immune responses in models of BE and EAC, suggesting potential benefits for human chemoprevention strategies.
View Article and Find Full Text PDF

Barrett's esophagus (BE) is a precursor to esophageal adenocarcinoma (EAC), but its cellular origin and mechanism of neoplastic progression remain unresolved. Notch signaling, which plays a key role in regulating intestinal stem cell maintenance, has been implicated in a number of cancers. The kinase Dclk1 labels epithelial post-mitotic tuft cells at the squamo-columnar junction (SCJ), and has also been proposed to contribute to epithelial tumor growth.

View Article and Find Full Text PDF

Chronic inflammation induces Barrett's Esophagus (BE) which can advance to esophageal adenocarcinoma. Elevated levels of interleukin (IL)-1b, IL-6 and IL-8 together with activated nuclear factor-kappaB (NF-κB), have been identified as important mediators of tumorigenesis. The inflammatory milieu apart from cancer cells and infiltrating immune cells contains myofibroblasts (MFs) that express aSMA and Vimentin.

View Article and Find Full Text PDF
Article Synopsis
  • Barrett's esophagus (BE) is an inflammatory condition that can lead to esophageal adenocarcinoma (EAC) and is linked to caspase-1 signaling, which is important for inflammatory responses.
  • This study investigated how caspase-1 expression changes during the progression from normal esophageal tissue to BE and eventually to EAC using three models: a human cell line, a mouse model, and patient tissue samples.
  • The results showed that caspase-1 activity is significantly higher in BE tissues, and inhibiting caspase-1 reduced the secretion of inflammatory markers, suggesting that targeting this protein could help manage inflammation and disease progression in BE patients.
View Article and Find Full Text PDF

Background & Aims: Studies are needed to determine the mechanism by which Barrett's esophagus (BE) progresses to esophageal adenocarcinoma (EAC). Notch signaling maintains stem cells in the gastrointestinal tract and is dysregulated during carcinogenesis. We explored the relationship between Notch signaling and goblet cell maturation, a feature of BE, during EAC pathogenesis.

View Article and Find Full Text PDF

The aim of this study is to compare the proteome of Prnp-/- (Zürich I) gene-ablated mouse brains with wild-type mouse brains. Fluorescence two-dimensional-difference gel electrophoresis (DIGE) and isotope-coded protein labeling (ICPL) were applied for brain homogenates. Similar quantitative protein profiles ( View Article and Find Full Text PDF